Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Oxygenta Pharmaceutical Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Oxygenta Pharmaceutical Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Oxygenta Pharmaceuti - Intimation Of Submission Of Application For Reclassification Of Person Forming Part Of The Promoter /
-
Oxygenta Pharmaceuti - Intimation Of Book Closure And Cut-Off Date For The 32Nd Annual General Meeting Of Oxygenta Pharmaceut
-
Oxygenta Pharmaceuti - Reg. 34 (1) Annual Report.
-
Oxygenta Pharmaceuti - 32Nd Annual General Meeting To Be Held On Friday 19Th September, 2025.
-
Oxygenta Pharmaceuti - Intimation Under Regulation 31A Of The SEBI (LODR) Regulations, 2015 For Reclassification From 'Promo
-
Oxygenta Pharmaceuti - Board Meeting Outcome for Outcome Of Board Meeting And Other Matters Under Regulations 30 And 31A Of S
-
Oxygenta Pharmaceuti - Intimation Under Regulation 31A Of The SEBI (LODR) Regulations, 2015 For Reclassification From 'Promo
-
Oxygenta Pharmaceuti - Intimation Under Regulation 31A Of The SEBI (LODR) Regulations, 2015 For Reclassification From 'Promo
-
Oxygenta Pharmaceuti - Intimation Of Receipt Of Request Applications From Promoters For Reclassification In Accordance With R
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Resignation of Managing Director
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management
-
Oxygenta Pharmaceuti posts Q1 net loss of Rs 6.11 cr
-
Oxygenta Pharmaceuti - Appointment of Company Secretary and Compliance Officer
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management
-
Oxygenta Pharmaceuti - Quarterly Results For The Quarter Ended 30.06.2025.
-
Oxygenta Pharmaceuti - Board Meeting Outcome for Outcome Of Board Meeting For The Un-Audited Financial Results For Quarter En
-
Oxygenta Pharmaceuti - Board Meeting Intimation for The Meeting To Be Held On 14.08.2025
-
Oxygenta Pharmaceuti has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Oxygenta Pharmaceuti - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management
-
Oxygenta Pharmaceuti - Intimation Under Regulation 31A (10) Relating To Reclassification Of 'Promoter/Promoter Group Category
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Directorate
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Resignation of Director
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management Control
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management
-
Oxygenta Pharmaceuti posts Q4 net loss of Rs 2.15 cr
Key fundamentals
Evaluate the intrinsic value of Oxygenta Pharmaceutical Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 36.5919 | 37.1113 | 21.7934 | 17.4997 | 9.8685 |
| Liabilities | 36.5919 | 37.1113 | 21.7934 | 17.4997 | 9.8685 |
| Equity | 36.9835 | 33.4835 | 14.2013 | 14.2013 | 10.2013 |
| Gross Profit | -9.9947 | -9.6965 | -7.1168 | 1.4759 | 3.8424 |
| Net Profit | -10.2983 | -3.4793 | -11.5709 | -0.6104 | 2.9298 |
| Cash From Operating Activities | 2.6028 | -13.0496 | -1.6336 | -1.6799 | -1.6219 |
| NPM(%) | -9.42 | -8.77 | -37.34 | -1 | 5.63 |
| Revenue | 109.2986 | 39.6421 | 30.9874 | 60.5248 | 52.027 |
| Expenses | 119.2933 | 49.3386 | 38.1042 | 59.0488 | 48.1845 |
| ROE(%) | 52.43 | 17.71 | 58.91 | 3.1 | -14.91 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Oxygenta Pharmaceutical Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 802.00 | 0.50 | 72.66 | 44.26 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 116.91 | 6.94 | 376.90 | 161.28 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 21.30 | -1.07 | 0.00 | 334.86 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 879.30 | 2.33 | 0.00 | 152.09 | -604.77 | 0.00 |
Company Info
OXYGENTA PHARMACEUTICAL LIMITED was incorporated as Private Limited Company in the year 1990 and subsequently converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. 1990 - The company was incorporated and its main line of business was bulk drugs. 1994 - The company had entered into an MOU with ICD group BV of Netherlands. As per the agreement, ICD would purchase 36 tonnes a year of mebadazole and 12 tonnes of atenolol for a period of five years from the company. 1998 - The company was turned sick and was registered with BIFR. 2003 -The board of the company had approved to convert the unsecured loans of Rs 2 crore into 20 lakh equity shares of Rs 10 each. - The board had also proposed to increase the authorized capital to Rs 8 crore from the existing level of Rs 6 crore. 2006 - Mr. Y Ramachandra Reddy (joint managing director), Mr. E Rama Subba Reddy (director) and Mr. G Chandramoulieswar Reddy (director) had resigned from the board of directors of the company. 2007 - Board of directors of the company on 4th April had passed the resolution to extend the financial year of the company to 15 months. 2008 - The Board of the company had appointed Mr. MG Naidu as independent director of the company. 2022 -Company name has changed to Oxygenta Pharmaceutical Ltd. from S S Organics Ltd..
OXYGENTA PHARMACEUTICAL LIMITED was incorporated as Private Limited Company in the year 1990 and subsequently converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. 1990 - The company was incorporated and its main line of business was bulk drugs. 1994 - The company had entered into an MOU with ICD group BV of Netherlands. As per the agreement, ICD would purchase 36 tonnes a year of mebadazole and 12 tonnes of atenolol for a period of five years from the company. 1998 - The company was turned sick and was registered with BIFR. 2003 -The board of the company had approved to convert the unsecured loans of Rs 2 crore into 20 lakh equity shares of Rs 10 each. - The board had also proposed to increase the authorized capital to Rs 8 crore from the existing level of Rs 6 crore. 2006 - Mr. Y Ramachandra Reddy (joint managing director), Mr. E Rama Subba Reddy (director) and Mr. G Chandramoulieswar Reddy (director) had resigned from the board of directors of the company. 2007 - Board of directors of the company on 4th April had passed the resolution to extend the financial year of the company to 15 months. 2008 - The Board of the company had appointed Mr. MG Naidu as independent director of the company. 2022 -Company name has changed to Oxygenta Pharmaceutical Ltd. from S S Organics Ltd..
Read More
Parent Organisation
Oxygenta Pharmaceutical Ltd.
Founded
27/11/1990
Managing Director
NSE Symbol
FAQ
The current price of Oxygenta Pharmaceutical Ltd is
The 52-week high for Oxygenta Pharmaceutical Ltd is
The market capitalization of Oxygenta Pharmaceutical Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Oxygenta Pharmaceutical Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Oxygenta Pharmaceutical Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Oxygenta Pharmaceutical Ltd shares.
The CEO of Oxygenta Pharmaceutical Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
